Brokerages Set Enliven Therapeutics, Inc. (NASDAQ:ELVN) PT at $41.00

Enliven Therapeutics, Inc. (NASDAQ:ELVN) has been given a consensus recommendation of “Moderate Buy” by the five analysts that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 1 year target price among analysts that have covered the stock in the last year is $41.00.

ELVN has been the topic of a number of research reports. Wall Street Zen raised shares of Enliven Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Wednesday, January 21st.

Insider Buying and Selling at Enliven Therapeutics

In other Enliven Therapeutics news, insider Joseph P. Lyssikatos sold 20,000 shares of the stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $26.75, for a total transaction of $535,000.00. Following the completion of the sale, the insider owned 745,188 shares of the company’s stock, valued at approximately $19,933,779. This represents a 2.61% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Anish Patel sold 48,300 shares of the firm’s stock in a transaction that occurred on Friday, January 9th. The stock was sold at an average price of $27.99, for a total transaction of $1,351,917.00. Following the transaction, the chief operating officer owned 215,011 shares of the company’s stock, valued at approximately $6,018,157.89. The trade was a 18.34% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 259,280 shares of company stock worth $6,635,968. Insiders own 25.90% of the company’s stock.

Institutional Investors Weigh In On Enliven Therapeutics

Large investors have recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Enliven Therapeutics by 25.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock valued at $44,000 after buying an additional 594 shares during the period. BNP Paribas Financial Markets raised its position in shares of Enliven Therapeutics by 33.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock worth $75,000 after acquiring an additional 930 shares in the last quarter. Quantbot Technologies LP lifted its stake in shares of Enliven Therapeutics by 47.1% in the 2nd quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock valued at $90,000 after purchasing an additional 1,434 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Enliven Therapeutics during the 4th quarter valued at about $95,000. Finally, AlphaQuest LLC acquired a new stake in Enliven Therapeutics during the third quarter worth approximately $96,000. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Enliven Therapeutics Trading Up 1.1%

Enliven Therapeutics stock opened at $25.67 on Tuesday. The stock has a 50-day moving average price of $20.74 and a two-hundred day moving average price of $20.47. Enliven Therapeutics has a 12 month low of $13.30 and a 12 month high of $29.98. The company has a market capitalization of $1.52 billion, a PE ratio of -13.95 and a beta of 0.41.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.11. As a group, analysts predict that Enliven Therapeutics will post -1.95 earnings per share for the current fiscal year.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.